FLYSYN by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

FLYSYN is under clinical development by VERAXA Biotech and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

Hospitalized COVID-19 patients face triple the risk of multiorgan damage, study reveals

Researchers in the U.K. find that patients hospitalized with COVID-19 face a higher medium-term risk of multiorgan abnormalities, revealed through multiorgan MRI scans. The study

September 26, 2023

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits – Psychedelic Alpha

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already

September 30, 2024

The top medtech trends in 2024

The medical device industry is set up for an eventful year after weathering numerous challenges for the past four years due to the COVID-19 pandemic

January 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.